Lymphaticovenular Bypass for Lymphedema Management in Breast Cancer Patients: A Prospective Study
- 1 September 2010
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Plastic and Reconstructive Surgery
- Vol. 126 (3), 752-758
- https://doi.org/10.1097/prs.0b013e3181e5f6a9
Abstract
Lymphedema is a common and debilitating condition. Management options for lymphedema are limited and controversial. The purpose of this prospective study was to provide a preliminary analysis of lymphaticovenular bypass for the treatment of upper limb lymphedema in breast cancer patients. Twenty patients with upper extremity lymphedema secondary to treatment of breast cancer underwent lymphaticovenular bypass using a "supermicrosurgical" approach. The mean age of the patients was 54 years, 16 patients had received preoperative radiation therapy, and all patients had received axillary lymph node dissection. The mean duration of lymphedema was 4.8 years, and the mean volume differential of the lymphedematous arm compared with the unaffected arm was 34 percent. Evaluation included qualitative assessment and quantitative volumetric analysis before surgery and at 1 month, 3 months, 6 months, and 1 year after the procedure. The mean number of bypasses performed per patient was 3.5 (range, two to five), and the size of bypasses ranged from 0.3 to 0.8 mm. The mean operative time was 3.3 hours (range, 2 to 5 hours). Hospital stay was less than 24 hours for all patients. The mean follow-up time was 18 months. Nineteen patients (95 percent) reported symptom improvement following surgery, and 13 patients had quantitative improvement. The mean volume differential reduction was 29 percent at 1 month, 36 percent at 3 months, 39 percent at 6 months, and 35 percent at 1 year. No patients experienced postoperative complications or lymphedema exacerbation. Lymphaticovenular bypass may effectively reduce the severity of lymphedema in breast cancer patients. Long-term analysis is needed.Keywords
This publication has 36 references indexed in Scilit:
- Surgical Complications Associated With Sentinel Lymph Node Dissection (SLND) Plus Axillary Lymph Node Dissection Compared With SLND Alone in the American College of Surgeons Oncology Group Trial Z0011Journal of Clinical Oncology, 2007
- Morbidity of Sentinel Lymph Node Biopsy (SLN) Alone Versus SLN and Completion Axillary Lymph Node Dissection After Breast Cancer SurgeryAnnals of Surgery, 2007
- Lymphedema following axillary lymph node dissection for breast cancerSurgical Oncology, 2006
- Surgical Complications Associated With Sentinel Lymph Node Biopsy: Results From a Prospective International Cooperative Group TrialAnnals of Surgical Oncology, 2006
- Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancerBreast Cancer Research and Treatment, 2005
- A Randomized Comparison of Sentinel-Node Biopsy with Routine Axillary Dissection in Breast CancerNew England Journal of Medicine, 2003
- Arm Edema in Breast Cancer PatientsJNCI Journal of the National Cancer Institute, 2001
- Risk of lymphoedema following the treatment of breast cancerBritish Journal of Surgery, 1986
- CONSERVATIVE TREATMENT OF BREAST CANCER: RESULTS OF MANAGEMENT OF AXILLARY LYMPH NODE AREA IN 3353 PATIENTSThe Lancet, 1985
- Ten-Year Results of a Randomized Clinical Trial Comparing Radical Mastectomy and Total Mastectomy with or without RadiationNew England Journal of Medicine, 1985